Cargando…
Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy
Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828575/ https://www.ncbi.nlm.nih.gov/pubmed/35155258 http://dx.doi.org/10.3389/fonc.2022.823287 |
_version_ | 1784647878192398336 |
---|---|
author | Suárez, Gisela María Catalá, Mauricio Peña, Yadira Portela, Susana Añé-Kourí, Ana Laura González, Amnely Lorenzo-Luaces, Patricia Díaz, Manuel Molina, María de los A. Pereira, Karla Hernández, Jenysbel de la C. Ramos, Raúl Reyes, Mary Carmen Ledón, Nuris Mazorra, Zaima Crombet, Tania Lage, Agustin Saavedra, Danay |
author_facet | Suárez, Gisela María Catalá, Mauricio Peña, Yadira Portela, Susana Añé-Kourí, Ana Laura González, Amnely Lorenzo-Luaces, Patricia Díaz, Manuel Molina, María de los A. Pereira, Karla Hernández, Jenysbel de la C. Ramos, Raúl Reyes, Mary Carmen Ledón, Nuris Mazorra, Zaima Crombet, Tania Lage, Agustin Saavedra, Danay |
author_sort | Suárez, Gisela María |
collection | PubMed |
description | Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the immunotherapeutic potential could be crucial. The aim of this study was to evaluate the effect of Biomodulina T (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in the context of cancer disease. Additionally, whether these effects might induce a better response to CIMAvax-EGF, an epidermal growth factor (EGF) depleting immunotherapy. Eighteen advanced NSCLC patients were evaluated after being treated with platinum-based chemotherapy. We found that the frequency of terminally differentiated effector T cells re-expressing CD45RA (EMRA) CD4+ (p=0.0031) and CD8+ (p=0.0372) T cells decreased with the administration of BT, whereas CD4+ naive T cells increase in more than 70% of the patients. Remarkably, CD4+ and CD8+ T lymphocytes expressing programmed cell death receptor-1 (PD1) significantly decreased after BT administration (p=0.0005 and p<0.0001, respectively). We also found an enhancement of the anti-EGF antibody response with a large percentage of patients treated with CIMAvax-EGF reaching the good antibody response condition after four vaccine doses. Moreover, the median overall survival of patients treated with CIMAvax-EGF was 16.09 months. In conclusion, our results suggest that the immunorestoration generated by the administration of BT after first-line chemotherapy may induce a better immune response to CIMAvax-EGF that could translate into the clinical benefit of patients diagnosed with advanced NSCLC. |
format | Online Article Text |
id | pubmed-8828575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88285752022-02-11 Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy Suárez, Gisela María Catalá, Mauricio Peña, Yadira Portela, Susana Añé-Kourí, Ana Laura González, Amnely Lorenzo-Luaces, Patricia Díaz, Manuel Molina, María de los A. Pereira, Karla Hernández, Jenysbel de la C. Ramos, Raúl Reyes, Mary Carmen Ledón, Nuris Mazorra, Zaima Crombet, Tania Lage, Agustin Saavedra, Danay Front Oncol Oncology Lung cancer is the second cause of cancer related deaths worldwide. Chemotherapy and immunotherapy represent the current standard of care for advanced NSCLC. Platinum-based chemotherapy expands late-differentiated T cell populations. Therefore, immune restoration after chemotherapy to adjuvate the immunotherapeutic potential could be crucial. The aim of this study was to evaluate the effect of Biomodulina T (BT), a thymic polypeptide fraction, on peripheral lymphocytes subpopulations in the context of cancer disease. Additionally, whether these effects might induce a better response to CIMAvax-EGF, an epidermal growth factor (EGF) depleting immunotherapy. Eighteen advanced NSCLC patients were evaluated after being treated with platinum-based chemotherapy. We found that the frequency of terminally differentiated effector T cells re-expressing CD45RA (EMRA) CD4+ (p=0.0031) and CD8+ (p=0.0372) T cells decreased with the administration of BT, whereas CD4+ naive T cells increase in more than 70% of the patients. Remarkably, CD4+ and CD8+ T lymphocytes expressing programmed cell death receptor-1 (PD1) significantly decreased after BT administration (p=0.0005 and p<0.0001, respectively). We also found an enhancement of the anti-EGF antibody response with a large percentage of patients treated with CIMAvax-EGF reaching the good antibody response condition after four vaccine doses. Moreover, the median overall survival of patients treated with CIMAvax-EGF was 16.09 months. In conclusion, our results suggest that the immunorestoration generated by the administration of BT after first-line chemotherapy may induce a better immune response to CIMAvax-EGF that could translate into the clinical benefit of patients diagnosed with advanced NSCLC. Frontiers Media S.A. 2022-01-27 /pmc/articles/PMC8828575/ /pubmed/35155258 http://dx.doi.org/10.3389/fonc.2022.823287 Text en Copyright © 2022 Suárez, Catalá, Peña, Portela, Añé-Kourí, González, Lorenzo-Luaces, Díaz, Molina, Pereira, Hernández, Ramos, Reyes, Ledón, Mazorra, Crombet, Lage and Saavedra https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Suárez, Gisela María Catalá, Mauricio Peña, Yadira Portela, Susana Añé-Kourí, Ana Laura González, Amnely Lorenzo-Luaces, Patricia Díaz, Manuel Molina, María de los A. Pereira, Karla Hernández, Jenysbel de la C. Ramos, Raúl Reyes, Mary Carmen Ledón, Nuris Mazorra, Zaima Crombet, Tania Lage, Agustin Saavedra, Danay Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title | Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_full | Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_fullStr | Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_full_unstemmed | Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_short | Thymic Polypeptide Fraction Biomodulina T Decreases Exhausted and Terminally Differentiated EMRA T Cells in Advanced Lung Cancer Patients Treated With Platinum-Based Chemotherapy |
title_sort | thymic polypeptide fraction biomodulina t decreases exhausted and terminally differentiated emra t cells in advanced lung cancer patients treated with platinum-based chemotherapy |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828575/ https://www.ncbi.nlm.nih.gov/pubmed/35155258 http://dx.doi.org/10.3389/fonc.2022.823287 |
work_keys_str_mv | AT suarezgiselamaria thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT catalamauricio thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT penayadira thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT portelasusana thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT anekourianalaura thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT gonzalezamnely thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT lorenzoluacespatricia thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT diazmanuel thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT molinamariadelosa thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT pereirakarla thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT hernandezjenysbeldelac thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT ramosraul thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT reyesmarycarmen thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT ledonnuris thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT mazorrazaima thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT crombettania thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT lageagustin thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy AT saavedradanay thymicpolypeptidefractionbiomodulinatdecreasesexhaustedandterminallydifferentiatedemratcellsinadvancedlungcancerpatientstreatedwithplatinumbasedchemotherapy |